Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Other Non Operating Income (2016 - 2025)

Karyopharm Therapeutics' Other Non Operating Income history spans 13 years, with the latest figure at -$62.4 million for Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 336.07% year-over-year to -$62.4 million; the TTM value through Dec 2025 reached -$52.2 million, down 227.52%, while the annual FY2025 figure was -$62.4 million, 239.51% down from the prior year.
  • Other Non Operating Income reached -$62.4 million in Q4 2025 per KPTI's latest filing, down from -$7.4 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $26.4 million in Q4 2024 to a low of -$62.4 million in Q4 2025.
  • Average Other Non Operating Income over 5 years is -$663000.0, with a median of $1500.0 recorded in 2022.
  • Peak YoY movement for Other Non Operating Income: crashed 608.57% in 2023, then skyrocketed 47553.33% in 2024.
  • A 5-year view of Other Non Operating Income shows it stood at -$478000.0 in 2021, then soared by 114.64% to $70000.0 in 2022, then plummeted by 608.57% to -$356000.0 in 2023, then skyrocketed by 7520.79% to $26.4 million in 2024, then crashed by 336.07% to -$62.4 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Other Non Operating Income are -$62.4 million (Q4 2025), -$7.4 million (Q3 2025), and -$2.2 million (Q2 2025).